We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19

By LabMedica International staff writers
Posted on 29 Sep 2021

NGeneBio (Seoul, Korea) showcased its next-generation sequencing (NGS)-based oncology/genetic diseases kits and NGenePlex nCoV qRT-PCR kit against COVID-19 at AACC 2021.

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.


Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)
Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)

At AACC 2021, NGeneBio showcased its NGS-based oncology/genetic diseases kits (BRCA/HEME/SOLID/ONCO/HLA). NGeneBio’s BRCAaccuTest and BRCAaccuTest PLUS are a reagent kit for producing libraries for analyzing the BRCA1 and BRCA2 genes using the NGS method, which analyzes genomic DNA derived from blood or FFPE tissue. The kit is intended for breast and ovarian cancer patients, HBOC (Hereditary breast and ovarian cancer syndrome) patients, and for family history or the age of breast cancer incidence.

Also on display at the event were NGeneBio’s HEMEaccuTest for molecular genetic test of multiple genes related hematologic malignancy; SOLIDaccuTest to explorer variants associated with solid tumors using a comprehensive method of NGS; HLAaccuTest All which is an in vitro diagnostic medical device for HLA (human leukocyte antigen) typing that can identify high-resolution histocompatibility antigens using NGS; and ONCOaccuPanel, a comprehensive solid tumor oncology NGS test.

In addition, NGeneBio demonstrated its NGeneAnalySys software for analysis of the genetic testing data produced by NGS and helps to report in clinical-grade for oncology test, alongside the EasyHLAanalyzer which provides the HLA typing identifying human leukocyte antigen for histocompatibility antigens using data from NGS. Also on display at AACC 2021 was NGeneBio’s NGenePlex nCoV qRT-PCR Kit which is a reagent of real-time reverse transcription-polymerase chain reaction (RT-PCR) assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19.

Related Links:
NGeneBio 


Gold Member
Turnkey Packaging Solution
HLX
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Newborn Screening Test
NeoMass AAAC 3.0
New
Electroporation System
Gibco CTS Xenon

Latest AACC 2021 News

Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021

Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines

Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting